Back to Clinical Trials

Brief Title: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

INTRODUCTION

  • Org Study ID: NCI-2019-01266
  • Secondary ID: NCI-2019-01266, A031702, A031702, U10CA180821
  • NTC ID: NCT03866382
  • Sponsor: National Cancer Institute (NCI)

BRIEF SUMMARY

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

DETAILED DESCRIPTION

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR).

SECONDARY OBJECTIVES:

I. To estimate the progression-free survival (PFS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

II. To estimate the overall survival (OS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

III. To estimate the clinical benefit rate (defined as complete response [CR] or partial response [PR] or stable disease [SD]) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

IV. To assess the safety of treating patients with rare variant histologies with cabozantinib combined with nivolumab and ipilimumab.

V. To support tissue banking and collection of clinical follow-up data for GU tract rare histological variants.

EXPLORATORY OBJECTIVES:

I. To assess effects of treatment in patients with bone-only disease by bone scan.

OUTLINE:

Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 5 years.

  • Overall Status
    Recruiting
  • Start Date
    April 12, 2019
  • Phase
    Phase 2
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Objective response rate (ORR)

Primary Outcome 1 - Timeframe: Up to 5 years

CONDITION

  • Bladder Adenocarcinoma
  • Bladder Clear Cell Adenocarcinoma
  • Bladder Mixed Adenocarcinoma
  • Bladder Neuroendocrine Carcinoma
  • Bladder Small Cell Neuroendocrine Carcinoma
  • Bladder Squamous Cell Carcinoma
  • Bladder Urachal Adenocarcinoma
  • Chromophobe Renal Cell Carcinoma
  • Collecting Duct Carcinoma
  • Infiltrating Bladder Lymphoepithelioma-Like Carcinoma
  • Infiltrating Bladder Urothelial Carcinoma
  • Infiltrating Bladder Urothelial Carcinoma With Giant Cells
  • Infiltrating Bladder Urothelial Carcinoma
  • Nested Variant
  • Infiltrating Bladder Urothelial Carcinoma
  • Plasmacytoid Variant
  • Infiltrating Bladder Urothelial Carcinoma
  • Sarcomatoid Variant
  • Kidney Medullary Carcinoma
  • Large Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Carcinoma
  • Metastatic Bladder Large Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Small Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Squamous Cell Carcinoma
  • Metastatic Infiltrating Bladder Urothelial Carcinoma
  • Clear Cell Variant
  • Metastatic Infiltrating Bladder Urothelial Carcinoma
  • Lipid-Rich Variant
  • Metastatic Infiltrating Bladder Urothelial Carcinoma
  • Micropapillary Variant
  • Metastatic Infiltrating Bladder Urothelial Carcinoma
  • Plasmacytoid Variant
  • Metastatic Infiltrating Bladder Urothelial Carcinoma
  • Sarcomatoid Variant
  • Metastatic Kidney Medullary Carcinoma
  • Metastatic Malignant Genitourinary System Neoplasm
  • Metastatic Penile Carcinoma
  • Metastatic Prostate Small Cell Neuroendocrine Carcinoma
  • Metastatic Sarcomatoid Renal Cell Carcinoma
  • Metastatic Urethral Carcinoma
  • Papillary Renal Cell Carcinoma
  • Sarcomatoid Renal Cell Carcinoma
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IV Prostate Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8
  • Stage IVA Bladder Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8
  • Stage IVB Bladder Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8
  • Testicular Leydig Cell Tumor
  • Testicular Sertoli Cell Tumor
  • Urethral Clear Cell Adenocarcinoma

ELIGIBILITY

Inclusion Criteria:
Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:
One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1

- One bone lesion on bone scan (tec99 or sodium fluoride [NaF] positron emission tomography [PET]/computed tomography [CT], CT, or magnetic resonance imaging [MRI]) for the bone-only cohort
Histologically confirmed diagnosis of one of the following metastatic cohorts:
Small cell/ neuroendocrine carcinoma of the bladder - All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded.

- Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma - must be pure (per World Health Organization [WHO] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma.

- Squamous cell carcinoma of the bladder - must be pure (i.e. urothelial carcinoma with squamous differentiation is not considered a pure squamous cell carcinoma).

- Plasmacytoid urothelial carcinoma - Tumor should show predominantly > or equal ~50% plasmacytoid histology (including all types of discohesive growth, such as tumors with signet-ring and/or rhabdoid features as well).

- Any penile cancer

- Sarcomatoid renal cell carcinoma - Tumor should be predominantly sarcomatoid ~50% (including rhabdoid differentiation) is also unclassified renal cell carcinomas (RCCs): all (assuming they are high grade with metastasis) malignant angiomyolipomas are allowed.

- Sarcomatoid urothelial carcinoma - Tumor should show predominantly ~ 50% sarcomatoid differentiation.

- Renal medullary carcinoma - Per WHO definition, ideally confirmed with immunostains.

- Renal collecting duct carcinoma - Per WHO definition (medullary involvement, predominant tubular morphology, desmoplastic stromal reaction, high grade cytology, infiltrative growth pattern, and absence of other renal cell carcinoma subtype or urothelial carcinoma).

- Bone only urothelial carcinoma or other non-prostate GU tumor

- Urethra carcinoma - May be of any histology but if urothelial carcinoma then must be isolated to the urethra and not have metachronous or synchronous urothelial carcinoma of the bladder.
Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to: micropapillary (Tumor should show predominantly > or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly > or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed. Post-treatment small cell prostatic carcinomas are not allowed), Malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC.
Note: Translocation positive renal cell carcinoma patients are eligible. However, AREN1721 should be considered before this trial.

- Hematoxylin and eosin (H&E) slides from diagnostic tumor tissue for retrospective central pathology review

- Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment). Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible).

- Patients must be able to swallow oral formulation of the tablets

- Karnofsky performance status >= 80%

- Absolute neutrophil count (ANC) >= 1,000/mcL

- Platelet count >= 75,000/mcL

- Total bilirubin =< 1.5 x upper limit of normal (ULN). For subjects with known Gilbert's disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =< 3.0 mg/dL - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN) (or =< 5 x ULN for patients with liver metastases or Gilbert's disease) - Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance >= 40 mL/min/1.73 m^2 (calculated using the Chronic Kidney Disease Epidemiology [CKD-EPI] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal

- Hemoglobin >= 9 g/dL (transfusion of packed red blood cells [PRBCs] allowed)

- Serum albumin >= 3.2 g/dL

- Lipase and amylase =< 2.0 x ULN and no radiologic (on baseline anatomical imaging) or clinical evidence of pancreatitis - Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed - Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors is allowed, either in the perioperative or in the metastatic setting. However, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are not allowed - Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable - Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication only and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies etc. are eligible but should be considered for rheumatologic evaluation for the presence of target organ involvement and potential need for systemic treatment - Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (e.g. thyroiditis managed with propylthiouracil [PTU] or methimazole) including physiologic oral corticosteroids are eligible - Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible
Women of childbearing potential must have a negative pregnancy test =< 7 days prior to registration
Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea >= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason

- Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents

- The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment
The patient has received no radiation therapy:
To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy

- To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment

- To the abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy

- To any other site(s) within 2 weeks before the first dose of study treatment

- The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment

- The patient has received no prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment

- The patient has received no prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. Subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate

- The patient has not received any other type of investigational agent within 14 days before the first dose of study treatment

- The patient must have recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae - The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans for subjects with known brain metastases is required to confirm eligibility - No concomitant treatment with warfarin. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted
No chronic concomitant treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort) or strong CYP3A4 inhibitors
Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
The patient has not experienced any of the following:
Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment

- Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood per day within 1 months before the first dose of study treatment

- Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment

- The patient has no tumor invading any major blood vessels

- The patient has no evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib. Patients with rectal tumor masses are not eligible.
The patient has no uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
Cardiovascular disorders including:
Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening.

- Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment

- The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard - Any history of congenital long QT syndrome
Any of the following within 6 months before registration of study treatment:
Unstable angina pectoris

- Clinically-significant cardiac arrhythmias (patients with atrial fibrillation are eligible)

- Stroke (including transient ischemic attack [TIA], or other ischemic event)

- Myocardial infarction

- Cardiomyopathy
No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:
Any of the following that have not resolved within 28 days before the first dose of study treatment:
Active peptic ulcer disease

- Acute diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or malabsorption syndrome
None of the following within 2 years before the first dose of study treatment:
Abdominal fistula or genitourinary fistula

- Gastrointestinal perforation

- Bowel obstruction or gastric outlet obstruction

- Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 2 years before the first dose of study treatment

- Disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement are not eligible
No other clinically significant disorders such as:
Severe active infection requiring IV systemic treatment within 14 days before the first dose of study treatment

- Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment

- History of organ or allogeneic stem cell transplant

- Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid-stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)
No history of major surgery as follows:
Major surgery within 3 months of the first dose of ca

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Andrea B Apolo

Role: Principal Investigator

Affiliation: Alliance for Clinical Trials in Oncology

Overall Contact

Name: Andrea B Apolo

Phone: N/A

Email: N/A

LOCATION

Facility Status Contact
Facility: University of Alabama at Birmingham Cancer Center
Birmingham, Alabama 35233
United States
Status: Recruiting Contact: Contact
Site Public Contact
205-934-0220
tmyrick@uab.edu
Facility: Mayo Clinic Hospital in Arizona
Phoenix, Arizona 85054
United States
Status: Recruiting Contact: Principal Investigator
Uzair B. Chaudhary
510-204-1414
mccinfo@mtcancer.org
Facility: Mayo Clinic in Arizona
Scottsdale, Arizona 85259
United States
Status: Recruiting Contact: Contact
Site Public Contact
510-465-8016
mccinfo@mtcancer.org
Facility: Banner University Medical Center - Tucson
Tucson, Arizona 85719
United States
Status: Recruiting Contact: Contact
Site Public Contact
308-398-6518
cancerclinicaltrials@bsd.uchicago.edu
Facility: University of Arizona Cancer Center-North Campus
Tucson, Arizona 85719
United States
Status: Recruiting Contact: Principal Investigator
Lisa Bailey
308-398-6518
Research@carle.com
Facility: Community Cancer Institute
Clovis, California 93611
United States
Status: Recruiting Contact: Principal Investigator
Anishka D'Souza
406-969-6060
cancerclinicaltrials@bsd.uchicago.edu
Facility: Epic Care-Dublin
Dublin, California 94568
United States
Status: Recruiting Contact: Principal Investigator
Lisa Bailey
406-969-6060
clinical.trials@daytonncorp.org
Facility: Bay Area Breast Surgeons Inc
Emeryville, California 94608
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
ksoder@mcfarlandclinic.com
Facility: Epic Care Partners in Cancer Care
Emeryville, California 94608
United States
Status: Recruiting Contact: Principal Investigator
Lisa Bailey
312-942-5498
Stephanie.Norris@LMH.ORG
Facility: Los Angeles County-USC Medical Center
Los Angeles, California 90033
United States
Status: Recruiting Contact: Principal Investigator
Lisa Bailey
773-702-8222
jennifer.jameson@ascension.org
Facility: USC / Norris Comprehensive Cancer Center
Los Angeles, California 90033
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-446-5532
mleepers@srhc.com
Facility: Contra Costa Regional Medical Center
Martinez, California 94553-3156
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-876-4762
Gregory.Johnstone@ochsner.org
Facility: Alta Bates Summit Medical Center - Summit Campus
Oakland, California 94609
United States
Status: Recruiting Contact: Contact
Site Public Contact
708-226-4357
emede1@lsuhsc.edu
Facility: Epic Care Cyberknife Center
Walnut Creek, California 94597
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-545-7929
cancerclinicaltrials@lahey.org
Facility: Porter Adventist Hospital
Denver, Colorado 80210
United States
Status: Recruiting Contact: Principal Investigator
Mehmet A. Bilen
800-446-5532
stephanie.couch@stjoeshealth.org
Facility: Littleton Adventist Hospital
Littleton, Colorado 80122
United States
Status: Recruiting Contact: Principal Investigator
John M. Schallenkamp
515-956-4132
stephanie.couch@stjoeshealth.org
Facility: Parker Adventist Hospital
Parker, Colorado 80138
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-956-4132
CTOResearch@hfhs.org
Facility: Holy Cross Hospital
Fort Lauderdale, Florida 33308
United States
Status: Recruiting Contact: Contact
Site Public Contact
620-235-7900
stephanie.couch@stjoeshealth.org
Facility: Orlando Health Cancer Institute
Orlando, Florida 32806
United States
Status: Recruiting Contact: Principal Investigator
Alan Tan
913-588-3671
stephanie.couch@stjoeshealth.org
Facility: Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
United States
Status: Recruiting Contact: Principal Investigator
Natalie Reizine
504-703-8712
stephanie.couch@stjoeshealth.org
Facility: Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho 83706
United States
Status: Recruiting Contact: Contact
Site Public Contact
504-210-3539
stephanie.couch@stjoeshealth.org
Facility: Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho 83605
United States
Status: Recruiting Contact: Contact
Site Public Contact
504-703-8712
stephanie.couch@stjoeshealth.org
Facility: Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho 83814
United States
Status: Recruiting Contact: Principal Investigator
Vamsi K. Vasireddy
800-411-1222
tpearce1@hfhs.org
Facility: Saint Alphonsus Medical Center-Nampa
Nampa, Idaho 83686
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org
Facility: Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho 83854
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org
Facility: Kootenai Cancer Clinic
Sandpoint, Idaho 83864
United States
Status: Recruiting Contact: Principal Investigator
Walter M. Stadler
734-712-3671
CancerTrials@EssentiaHealth.org
Facility: Rush University Medical Center
Chicago, Illinois 60612
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
info@siteman.wustl.edu
Facility: University of Illinois
Chicago, Illinois 60612
United States
Status: Recruiting Contact: Principal Investigator
Vamsi K. Vasireddy
734-712-3671
mccinfo@mtcancer.org
Facility: University of Chicago Comprehensive Cancer Center
Chicago, Illinois 60637
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
research@billingsclinic.org
Facility: Carle on Vermilion
Danville, Illinois 61832
United States
Status: Recruiting Contact: Principal Investigator
Howard M. Gross
734-712-3671
mccinfo@mtcancer.org
Facility: Carle Physician Group-Effingham
Effingham, Illinois 62401
United States
Status: Recruiting Contact: Principal Investigator
Debra M. Prow
734-712-3671
unmcrsa@unmc.edu
Facility: Crossroads Cancer Center
Effingham, Illinois 62401
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-916-1784
unmcrsa@unmc.edu
Facility: Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
clinical.trials@daytonncorp.org
Facility: Loyola University Medical Center
Maywood, Illinois 60153
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth M. Wulff-Burchfield
218-786-3308
clinical.trials@daytonncorp.org
Facility: UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois 60451
United States
Status: Recruiting Contact: Contact
Site Public Contact
952-993-1517
sheree@columbusccop.org
Facility: Cancer Care Center of O'Fallon
O'Fallon, Illinois 62269
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth M. Wulff-Burchfield
218-786-3308
sheree@columbusccop.org
Facility: University of Chicago Medicine-Orland Park
Orland Park, Illinois 60462
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
sheree@columbusccop.org
Facility: Southern Illinois University School of Medicine
Springfield, Illinois 62702
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
sheree@columbusccop.org
Facility: Springfield Clinic
Springfield, Illinois 62702
United States
Status: Recruiting Contact: Principal Investigator
Peng Wang
314-996-5569
sheree@columbusccop.org
Facility: Memorial Medical Center
Springfield, Illinois 62781
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
clinical.trials@daytonncorp.org
Facility: Carle Cancer Center
Urbana, Illinois 61801
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
clinical.trials@daytonncorp.org
Facility: Reid Health
Richmond, Indiana 47374
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
sheree@columbusccop.org
Facility: Mary Greeley Medical Center
Ames, Iowa 50010
United States
Status: Recruiting Contact: Principal Investigator
Scott E. Delacroix
800-996-2663
sheree@columbusccop.org
Facility: McFarland Clinic PC - Ames
Ames, Iowa 50010
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
sheree@columbusccop.org
Facility: McFarland Clinic PC-Boone
Boone, Iowa 50036
United States
Status: Recruiting Contact: Principal Investigator
Pedro M. Barata
406-969-6060
sheree@columbusccop.org
Facility: McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa 50501
United States
Status: Recruiting Contact: Contact
Site Public Contact
702-384-0013
CanRsrchStudies@providence.org
Facility: McFarland Clinic PC-Jefferson
Jefferson, Iowa 50129
United States
Status: Recruiting Contact: Principal Investigator
Brendan Connell
702-384-0013
mccinfo@mtcancer.org
Facility: McFarland Clinic PC-Marshalltown
Marshalltown, Iowa 50158
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592
CanRsrchStudies@providence.org
Facility: HaysMed University of Kansas Health System
Hays, Kansas 67601
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-305-6361
canceranswerline@UTSouthwestern.edu
Facility: Lawrence Memorial Hospital
Lawrence, Kansas 66044
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
585-275-5830
research@kadlecmed.org
Facility: Olathe Health Cancer Center
Olathe, Kansas 66061
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
ncorp@aurora.org
Facility: Ascension Via Christi - Pittsburg
Pittsburg, Kansas 66762
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-779-7585
ncorp@aurora.org
Facility: Salina Regional Health Center
Salina, Kansas 67401
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
614-488-2118
ncorp@aurora.org
Facility: University of Kansas Health System Saint Francis Campus
Topeka, Kansas 66606
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-566-4475
ncorp@aurora.org
Facility: University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-488-2118
ncorp@aurora.org
Facility: University of Kentucky/Markey Cancer Center
Lexington, Kentucky 40536
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
937-528-2900
Facility: Ochsner High Grove
Baton Rouge, Louisiana 70836
United States
Status: Recruiting Contact: Contact
Site Public Contact
740-393-9000
Facility: Ochsner Medical Center Kenner
Kenner, Louisiana 70065
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
740-348-4000
Facility: East Jefferson General Hospital
Metairie, Louisiana 70006
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-488-2118
Facility: LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie, Louisiana 70006
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
937-528-2900
Facility: Tulane University Health Sciences Center
New Orleans, Louisiana 70112
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
740-454-5232
Facility: Ochsner Medical Center Jefferson
New Orleans, Louisiana 70121
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-231-4440
Facility: National Institutes of Health Clinical Center
Bethesda, Maryland 20892
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
405-271-8777
Facility: Lahey Hospital and Medical Center
Burlington, Massachusetts 01805
United States
Status: Recruiting Contact: Contact
Site Public Contact
918-505-3200
Facility: Lahey Medical Center-Peabody
Peabody, Massachusetts 01960
United States
Status: Recruiting Contact: Principal Investigator
Ding Wang
503-215-2614
Facility: Winchester Hospital
Winchester, Massachusetts 01890
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
406-969-6060
Facility: Saint Joseph Mercy Hospital
Ann Arbor, Michigan 48106
United States
Status: Recruiting Contact: Contact
Site Public Contact
503-215-2614
Facility: IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan 48114
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
503-215-2614
Facility: Saint Joseph Mercy Brighton
Brighton, Michigan 48114
United States
Status: Recruiting Contact: Contact
Site Public Contact
503-494-1080
Facility: IHA Hematology Oncology Consultants-Canton
Canton, Michigan 48188
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
Facility: Saint Joseph Mercy Canton
Canton, Michigan 48188
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
814-452-5000
Facility: IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan 48118
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
412-858-7746
Facility: Saint Joseph Mercy Chelsea
Chelsea, Michigan 48118
United States
Status: Recruiting Contact: Contact
Site Public Contact
724-226-7380
Facility: Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan 48038
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
843-792-9321
Facility: Henry Ford Hospital
Detroit, Michigan 48202
United States
Status: Recruiting Contact: Principal Investigator
Bret E. Friday
214-648-7097
Facility: Ascension Saint John Hospital
Detroit, Michigan 48236
United States
Status: Recruiting Contact: Contact
Site Public Contact
214-648-7097
Facility: Great Lakes Cancer Management Specialists-Doctors Park
East China Township, Michigan 48054
United States
Status: Recruiting Contact: Principal Investigator
Bret E. Friday
972-669-7044
Facility: Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan 48503
United States
Status: Recruiting Contact: Contact
Site Public Contact
308-398-6518
Facility: Genesee Hematology Oncology PC
Flint, Michigan 48503
United States
Status: Recruiting Contact: Principal Investigator
Bret E. Friday
509-783-4637
Facility: Genesys Hurley Cancer Institute
Flint, Michigan 48503
United States
Status: Recruiting Contact: Contact
Site Public Contact
425-228-3440
Facility: Hurley Medical Center
Flint, Michigan 48503
United States
Status: Recruiting Contact: Principal Investigator
Lance C. Pagliaro
218-786-3308
Facility: Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan 48236
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
Facility: Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan 48236
United States
Status: Recruiting Contact: Principal Investigator
Daniel M. Anderson
855-776-0015
Facility: Sparrow Hospital
Lansing, Michigan 48912
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
Facility: Hope Cancer Clinic
Livonia, Michigan 48154
United States
Status: Recruiting Contact: Principal Investigator
Bret E. Friday
414-302-2304
Facility: Saint Mary Mercy Hospital
Livonia, Michigan 48154
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
Facility: Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan 48044
United States
Status: Recruiting Contact: Principal Investigator
John C. Henegan
414-302-2304
Facility: Ascension Saint Mary's Hospital
Saginaw, Michigan 48601
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
Facility: Oncology Hematology Associates of Saginaw Valley PC
Saginaw, Michigan 48604
United States
Status: Recruiting Contact: Principal Investigator
Joel Picus
414-302-2304
Facility: Henry Ford Macomb Health Center - Shelby Township
Shelby, Michigan 48315
United States
Status: Recruiting Contact: Contact
Site Public Contact
787-407-3333
Facility: Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, Michigan 48312
United States
Status: Recruiting Contact: Principal Investigator
Joel Picus

Facility: Ascension Saint Joseph Hospital
Tawas City, Michigan 48764
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, Michigan 48093
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Saint John Macomb-Oakland Hospital
Warren, Michigan 48093
United States
Status: Recruiting Contact: Principal Investigator
Jay W. Carlson

Facility: Saint Mary's Oncology/Hematology Associates of West Branch
West Branch, Michigan 48661
United States
Status: Recruiting Contact: Principal Investigator
Joel Picus

Facility: Huron Gastroenterology PC
Ypsilanti, Michigan 48106
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: IHA Hematology Oncology Consultants-Ann Arbor
Ypsilanti, Michigan 48197
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller

Facility: Essentia Health - Deer River Clinic
Deer River, Minnesota 56636
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Essentia Health Cancer Center
Duluth, Minnesota 55805
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Essentia Health Hibbing Clinic
Hibbing, Minnesota 55746
United States
Status: Recruiting Contact: Principal Investigator
John M. Schallenkamp

Facility: Mayo Clinic in Rochester
Rochester, Minnesota 55905
United States
Status: Recruiting Contact: Principal Investigator
John A. Ellerton

Facility: Regions Hospital
Saint Paul, Minnesota 55101
United States
Status: Recruiting Contact: Principal Investigator
Samuel A. Funt

Facility: Essentia Health Sandstone
Sandstone, Minnesota 55072
United States
Status: Recruiting Contact: Principal Investigator
Samuel A. Funt

Facility: Essentia Health Virginia Clinic
Virginia, Minnesota 55792
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: University of Mississippi Medical Center
Jackson, Mississippi 39216
United States
Status: Recruiting Contact: Principal Investigator
Samuel A. Funt

Facility: Saint Francis Medical Center
Cape Girardeau, Missouri 63703
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri 63141
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Parkland Health Center - Farmington
Farmington, Missouri 63640
United States
Status: Recruiting Contact: Principal Investigator
Samuel A. Funt

Facility: Truman Medical Centers
Kansas City, Missouri 64108
United States
Status: Recruiting Contact: Principal Investigator
Paul M. Barr

Facility: University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri 64064
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Washington University School of Medicine
Saint Louis, Missouri 63110
United States
Status: Recruiting Contact: Principal Investigator
James E. Radford

Facility: Siteman Cancer Center-South County
Saint Louis, Missouri 63129
United States
Status: Recruiting Contact: Principal Investigator
Timothy D. Moore

Facility: Missouri Baptist Medical Center
Saint Louis, Missouri 63131
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Siteman Cancer Center at Christian Hospital
Saint Louis, Missouri 63136
United States
Status: Recruiting Contact: Principal Investigator
Howard M. Gross

Facility: Mercy Hospital Saint Louis
Saint Louis, Missouri 63141
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri 63376
United States
Status: Recruiting Contact: Principal Investigator
Howard M. Gross

Facility: Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
United States
Status: Recruiting Contact: Principal Investigator
Amir Mortazavi

Facility: Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri 63127
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Community Hospital of Anaconda
Anaconda, Montana 59711
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Billings Clinic Cancer Center
Billings, Montana 59101
United States
Status: Recruiting Contact: Principal Investigator
Timothy D. Moore

Facility: Bozeman Deaconess Hospital
Bozeman, Montana 59715
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana 59405
United States
Status: Recruiting Contact: Principal Investigator
Timothy D. Moore

Facility: Kalispell Regional Medical Center
Kalispell, Montana 59901
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Community Medical Hospital
Missoula, Montana 59804
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Nebraska Medicine-Bellevue
Bellevue, Nebraska 68123
United States
Status: Recruiting Contact: Principal Investigator
Timothy D. Moore

Facility: Nebraska Methodist Hospital
Omaha, Nebraska 68114
United States
Status: Recruiting Contact: Principal Investigator
Howard M. Gross

Facility: Nebraska Medicine-Village Pointe
Omaha, Nebraska 68118
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: University of Nebraska Medical Center
Omaha, Nebraska 68198
United States
Status: Recruiting Contact: Principal Investigator
Timothy D. Moore

Facility: OptumCare Cancer Care at Charleston
Las Vegas, Nevada 89102
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada 89148
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey 07920
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Memorial Sloan Kettering Monmouth
Middletown, New Jersey 07748
United States
Status: Recruiting Contact: Principal Investigator
Shifeng S. Mao

Facility: Memorial Sloan Kettering Bergen
Montvale, New Jersey 07645
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Maimonides Medical Center
Brooklyn, New York 11219
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Roswell Park Cancer Institute
Buffalo, New York 14263
United States
Status: Recruiting Contact: Principal Investigator
Shifeng S. Mao

Facility: Memorial Sloan Kettering Commack
Commack, New York 11725
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Memorial Sloan Kettering Westchester
Harrison, New York 10604
United States
Status: Recruiting Contact: Principal Investigator
Shifeng S. Mao

Facility: Northwell Health/Center for Advanced Medicine
Lake Success, New York 11042
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York 10032
United States
Status: Recruiting Contact: Principal Investigator
Shifeng S. Mao

Facility: Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: NYP/Weill Cornell Medical Center
New York, New York 10065
United States
Status: Recruiting Contact: Principal Investigator
Leonard J. Appleman

Facility: University of Rochester
Rochester, New York 14642
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Memorial Sloan Kettering Nassau
Uniondale, New York 11553
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina 27599
United States
Status: Recruiting Contact: Principal Investigator
Nancy B. Davis

Facility: Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina 28791
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Strecker Cancer Center-Belpre
Belpre, Ohio 45714
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Dayton Physicians LLC-Miami Valley South
Centerville, Ohio 45459
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Miami Valley Hospital South
Centerville, Ohio 45459
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming

Facility: Adena Regional Medical Center
Chillicothe, Ohio 45601
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: Mount Carmel East Hospital
Columbus, Ohio 43213
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Columbus Oncology and Hematology Associates Inc
Columbus, Ohio 43214
United States
Status: Recruiting Contact: Principal Investigator
Lance C. Pagliaro

Facility: Riverside Methodist Hospital
Columbus, Ohio 43214
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Grant Medical Center
Columbus, Ohio 43215
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: The Mark H Zangmeister Center
Columbus, Ohio 43219
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Mount Carmel Health Center West
Columbus, Ohio 43222
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: Doctors Hospital
Columbus, Ohio 43228
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Miami Valley Hospital
Dayton, Ohio 45409
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Dayton Physician LLC-Miami Valley Hospital North
Dayton, Ohio 45415
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: Miami Valley Hospital North
Dayton, Ohio 45415
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Delaware Health Center-Grady Cancer Center
Delaware, Ohio 43015
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: Grady Memorial Hospital
Delaware, Ohio 43015
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Armes Family Cancer Center
Findlay, Ohio 45840
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Dayton Physicians LLC-Atrium
Franklin, Ohio 45005
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Greater Dayton Cancer Center
Kettering, Ohio 45409
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: Kettering Medical Center
Kettering, Ohio 45429
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: Fairfield Medical Center
Lancaster, Ohio 43130
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: OhioHealth Mansfield Hospital
Mansfield, Ohio 44903
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Marietta Memorial Hospital
Marietta, Ohio 45750
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: OhioHealth Marion General Hospital
Marion, Ohio 43302
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Knox Community Hospital
Mount Vernon, Ohio 43050
United States
Status: Recruiting Contact: Principal Investigator
Rubina Qamar

Facility: Licking Memorial Hospital
Newark, Ohio 43055
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Southern Ohio Medical Center
Portsmouth, Ohio 45662
United States
Status: Recruiting Contact: Principal Investigator
Timothy R. Wassenaar

Facility: Springfield Regional Cancer Center
Springfield, Ohio 45504
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Saint Ann's Hospital
Westerville, Ohio 43081
United States
Status: Recruiting Contact: N/A
Facility: Genesis Healthcare System Cancer Care Center
Zanesville, Ohio 43701
United States
Status: Recruiting Contact: N/A
Facility: Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma 73505
United States
Status: Recruiting Contact: N/A
Facility: University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
United States
Status: Recruiting Contact: N/A
Facility: Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma 74146
United States
Status: Recruiting Contact: N/A
Facility: Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon 97015
United States
Status: Recruiting Contact: N/A
Facility: Providence Newberg Medical Center
Newberg, Oregon 97132
United States
Status: Recruiting Contact: N/A
Facility: Saint Alphonsus Medical Center-Ontario
Ontario, Oregon 97914
United States
Status: Recruiting Contact: N/A
Facility: Providence Portland Medical Center
Portland, Oregon 97213
United States
Status: Recruiting Contact: N/A
Facility: Providence Saint Vincent Medical Center
Portland, Oregon 97225
United States
Status: Recruiting Contact: N/A
Facility: Oregon Health and Science University
Portland, Oregon 97239
United States
Status: Recruiting Contact: N/A
Facility: Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania 18103
United States
Status: Recruiting Contact: N/A
Facility: Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania 18017
United States
Status: Recruiting Contact: N/A
Facility: Saint Vincent Hospital
Erie, Pennsylvania 16544
United States
Status: Recruiting Contact: N/A
Facility: Jefferson Hospital
Jefferson Hills, Pennsylvania 15025
United States
Status: Recruiting Contact: N/A
Facility: Forbes Hospital
Monroeville, Pennsylvania 15146
United States
Status: Recruiting Contact: N/A
Facility: Allegheny Valley Hospital
Natrona Heights, Pennsylvania 15065
United States
Status: Recruiting Contact: N/A
Facility: Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
United States
Status: Recruiting Contact: N/A
Facility: University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
United States
Status: Recruiting Contact: N/A
Facility: Medical University of South Carolina
Charleston, South Carolina 29425
United States
Status: Recruiting Contact: N/A
Facility: Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
United States
Status: Recruiting Contact: N/A
Facility: UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas 75390
United States
Status: Recruiting Contact: N/A
Facility: UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth, Texas 76104
United States
Status: Recruiting Contact: N/A
Facility: UT Southwestern Clinical Center at Richardson/Plano
Richardson, Texas 75080
United States
Status: Recruiting Contact: N/A
Facility: Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington 98310
United States
Status: Recruiting Contact: N/A
Facility: Kadlec Clinic Hematology and Oncology
Kennewick, Washington 99336
United States
Status: Recruiting Contact: N/A
Facility: Valley Medical Center
Renton, Washington 98055
United States
Status: Recruiting Contact: N/A
Facility: Duluth Clinic Ashland
Ashland, Wisconsin 54806
United States
Status: Recruiting Contact: N/A
Facility: Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin 53105
United States
Status: Recruiting Contact: N/A
Facility: Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin 54701
United States
Status: Recruiting Contact: N/A
Facility: Aurora Health Care Germantown Health Center
Germantown, Wisconsin 53022
United States
Status: Recruiting Contact: N/A
Facility: Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
United States
Status: Recruiting Contact: N/A
Facility: Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
United States
Status: Recruiting Contact: N/A
Facility: Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
United States
Status: Recruiting Contact: N/A
Facility: Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
United States
Status: Recruiting Contact: N/A
Facility: Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin 53209
United States
Status: Recruiting Contact: N/A
Facility: Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
United States
Status: Recruiting Contact: N/A
Facility: Aurora Sinai Medical Center
Milwaukee, Wisconsin 53233
United States
Status: Recruiting Contact: N/A
Facility: ProHealth D N Greenwald Center
Mukwonago, Wisconsin 53149
United States
Status: Recruiting Contact: N/A
Facility: ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin 53066
United States
Status: Recruiting Contact: N/A
Facility: Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
United States
Status: Recruiting Contact: N/A
Facility: Aurora Cancer Care-Racine
Racine, Wisconsin 53406
United States
Status: Recruiting Contact: N/A
Facility: Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin 53081
United States
Status: Recruiting Contact: N/A
Facility: Aurora Medical Center in Summit
Summit, Wisconsin 53066
United States
Status: Recruiting Contact: N/A
Facility: Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin 54241
United States
Status: Recruiting Contact: N/A
Facility: ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin 53188
United States
Status: Recruiting Contact: N/A
Facility: UW Cancer Center at ProHealth Care
Waukesha, Wisconsin 53188
United States
Status: Recruiting Contact: N/A
Facility: Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin 53226
United States
Status: Recruiting Contact: N/A
Facility: Aurora West Allis Medical Center
West Allis, Wisconsin 53227
United States
Status: Recruiting Contact: N/A
Facility: Pan American Center for Oncology Trials LLC
San Juan, 00902
Puerto Rico
Status: Recruiting Contact: N/A